Literature DB >> 21932254

Synthesis and anticancer activity of Indolin-2-one derivatives bearing the 4-thiazolidinone moiety.

Shuobing Wang1, Yanfang Zhao, Wufu Zhu, Ying Liu, Kaixing Guo, Ping Gong.   

Abstract

A novel series of indolin-2-one derivatives containing the 4-thiazolidinone moiety (5a-5p) was synthesized and the cytotoxicity of these derivatives was evaluated in vitro against three human cancer cell lines (HT-29, H460 and MDA-MB-231) by standard MTT assay. Some prepared compounds exhibited significant cytotoxicity against different human cancer cell lines. Several potent compounds were further evaluated against one normal cell line (WI-38). In particular, the promising compound 5h showed remarkable cytotoxicity and selectivity against the HT-29 and H460 cancer cell lines (IC(50)  = 0.016 µmol/L, 0.0037 µmol/L, respectively).
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932254     DOI: 10.1002/ardp.201100082

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  3 in total

1.  Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.

Authors:  Kamila K Kaminska; Helene C Bertrand; Hisashi Tajima; William C Stafford; Qing Cheng; Wan Chen; Geoffrey Wells; Elias S J Arner; Eng-Hui Chew
Journal:  Oncotarget       Date:  2016-06-28

Review 2.  5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry.

Authors:  Danylo Kaminskyy; Anna Kryshchyshyn; Roman Lesyk
Journal:  Eur J Med Chem       Date:  2017-09-20       Impact factor: 6.514

3.  Design, synthesis and biological evaluation of novel bromophenol derivatives incorporating indolin-2-one moiety as potential anticancer agents.

Authors:  Li-Jun Wang; Shuai-Yu Wang; Bo Jiang; Ning Wu; Xiang-Qian Li; Bao-Cheng Wang; Jiao Luo; Meng Yang; Shui-Hua Jin; Da-Yong Shi
Journal:  Mar Drugs       Date:  2015-02-02       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.